Nottingham-based Cellomatics Biosciences presented with Queen's Award for Enterprise

Nottingham-based contract research organisation (CRO) Cellomatics Biosciences has been officially presented with the prestigious Queen’s Award for Enterprise for International Trade following significant growth in its export business.

Cellomatics is one of just 232 organisations nationally to be recognised with the prominent award, which this year becomes the King’s Award for Enterprise.

The company was presented with the award by the Lord Lieutenant of Nottingham, Sir John Peace, on Thursday 23 March at a ceremony hosted at Cellomatics’ Head Office in Colwick. The afternoon event was attended by specially invited guests and clients, staff and the Lord Mayor of Nottingham, Cllr Wendy Smith. Founder and CEO of Cellomatics, Dr Shailendra Singh, received a commemorative crystal bowl in recognition of the company’s outstanding export achievements.

Employing 20 people, Cellomatics was founded in 2015 and specialises in the development of bespoke bioassays across numerous therapeutic areas including oncology, immuno-oncology, immunology, inflammation and respiratory.

In 2021, the company reported year-on-year organic growth of 30 percent since it was founded. In the wake of increased demand for its bespoke preclinical and early discovery phase laboratory services and expertise, Cellomatics moved into its purpose-built laboratories in Colwick in 2022.

The company’s export business has increased 15-fold, with significant growth from clients in Europe, Asia, and the USA. These export sales now represent approximately 50 percent of their total revenue.

Dr Shailendra Singh said: “We were honoured to receive the Queen’s Award for Enterprise from the Lord Lieutenant of Nottingham and are grateful to everyone who attended the event. I’d like to thank each and every member of the Cellomatics team for their support and the key role they have each played in helping us to achieve this feat.

“Since receiving the accolade last year, we have experienced a significant increase in the number of companies seeking our expertise and assistance in expediting their drug development programmes. We’re looking forward to continuing our growth trajectory and delivering quality results for our growing network of clients around the world.”

The Queen’s Award for Enterprise presentation comes after an extremely successful start to the year, which has seen the Cellomatics win both the Signature Award for Excellence in Technology, and the FSB Award for Exporter of the Year, as well as being shortlisted for the Export Achievement Award at the Medilink Midlands Business Awards.

For more information, visit: www.cellomaticsbio.com